The U.S. FDA has approved our therapy for certain people with pre-treated HR+/HER2- metastatic breast cancer.
Read more.

Access Partnerships

We work with a network of regional distributors to enable access to Gilead’s portfolio of medicines in low- and middle-income countries. We also work with, voluntary licensees, the Medicines Patent Pool and other stakeholders to expand treatment globally.

Regional Business Partners

Regional business partners serve as our on-the-ground interface with local governments, medical organizations, healthcare professionals and other stakeholders. In addition to delivering Gilead's HIV, viral hepatitis and COVID-19 treatments, partners are instrumental in registering medicines with regulatory authorities and assisting with medical and clinical education. 

Regional Business Partners List

  • Africphar
  • Amba Pharmaceuticals
  • Aspen Pharmacare
  • DCH Auriga
  • Delta Medical
  • Dinafa
  • Eva Pharma
  • Ferozsons Laboratories
  • Gador Pharmaceutical Exchange
  • Gador SA
  • Key Oncologics
  • Medical Access Uganda
  • MedImport
  • Menarini (Latin Farma)
  • MSJ Ltd. (Unicorn)
  • Mylan Pharmaceuticals
  • Oduber
  • Ombol
  • Phillips Pharmaceuticals
  • Puerto Rico Pharmaceuticals
  • Pulse Pharmaceuticals
  • Rite Chem
  • Soho
  • Stendhal
  • Sterelin Medical & Diagnostics
  • Stein Cares
  • United Medical
  • Zuellig Pharma

Voluntary Licensees

Generic drug manufacturers in India, China, South Africa, Egypt and Pakistan play a major role in expanding access to Gilead HIV, viral hepatitis and COVID-19 medicines in low- and middle-income countries. In 2021, HIV medicines were made available to an estimated 16.5 million people living with HIV in resource-limited countries around the world through organizations that benefited from Gilead’s licensing arrangements.

HIV and Hepatitis B Medicines Generic Licensees

  • Adcock Ingram Ltd.* (South Africa)
  • Alkem Laboratories Ltd.
  • Anhui Biochem Pharmaceutical* (China)
  • Arene Lifesciences Limited*
  • Aurobindo Pharma Ltd.*
  • Cadila Healthcare Ltd.
  • Cipla Ltd.*
  • Desano Pharmaceuticals Pvt. Ltd.*
  • Dr Reddy’s Laboratories Ltd.*
  • Emcure Pharmaceuticals Ltd.*
  • Hetero Labs Ltd.*
  • Laurus Labs Ltd.*
  • Lupin Limited*
  • Macleods Pharmaceuticals Ltd*
  • Mcneil & Argus Pharmaceuticals Ltd.
  • Micro Labs Ltd.*
  • Mylan Laboratories Ltd.
  • Natco Pharma Ltd*
  • Shanghai Desano Pharmaceuticals Ltd* (China)
  • Solara Active
  • Strides Shasun Ltd.
  • Sun Pharmaceuticals Industries Ltd
  • Unimark Remedies Ltd.
  • Zhejiang Langhua Pharmaceutical Co., Ltd* (China)

*Licensed via Medicines Patent Pool

Hepatitis C Medicines Generic Licensees

  • Aurobindo Pharma Ltd.
  • Biocon Limited
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Ferozsons Laboratories Ltd (for Pakistan only)
  • Hetero Labs Ltd.
  • Laurus Labs Pvt. Ltd.
  • Magic Pharma (for Egypt only)
  • Mylan Laboratories Ltd.
  • Natco Pharma Ltd.
  • Pharmed Healthcare (for Egypt only)
  • Solara Active Pharma Sciences
  • Strides Shasun Ltd.
  • Sun Pharmaceuticals Industries Ltd

COVID-19 Medicine Generic Licensees

  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Eva Pharma
  • Ferozsons Laboratories
  • Hetero Labs Ltd.
  • Jubilant Lifesciences
  • Mylan
  • Syngene, a Biocon company
  • Zydus Cadilla Healthcare Ltd.

Medicines Patent Pool

In 2011, Gilead was the first innovator pharmaceutical company to join the Medicines Patent Pool (MPP) to expand access to its medicines through the sharing of drug patents. The MPP was established by UNITAID, a Geneva-based global health organization that works to make high-quality, life-saving treatments and diagnostics more affordable in low-income countries. Details on the Gilead-MPP license for HIV and hepatitis B medicines are available here.